In vivo functional grade antibodies can take your research from initial hypothesis to in vivo animal studies
With their ability to activate, neutralize or block the activity of their antigen, these antibodies are powerful tools for elucidating the function of a specific protein as well as interrogating the physiological impact of disrupting the protein’s normal function. In vivo functional grade antibodies are suitable for numerous areas of research, including:
Western Blot: Expression levels of your targets
Flow Cytometry: Examine cellular population dynamics
Immunoprecipitation: Discover binding partners
Immunofluorescence: Subcellular localization of targets
Immunohistochemistry: Expression of targets in tissues
Spatial Phenotyping: Visualize how cells interact and organize in a tissue landscape
Name | Applications ? | Prod No. | Clone | Pkg. Size / Quantity |
|---|---|---|---|---|
Alt Names: PETA-3, Platelet-Endothelial tetra-span antigen, Tspan-24 Reactivity: Human Immunogen: Human epidermoid carcinoma cell line HEp-3 | B , CyTOF® , FC , ICC , in vivo , WB | C2039 | 50-6 | |
Alt Names: VLA-4α, ITGA4, Integrin α4 Reactivity: Mouse/Human Immunogen: P815 DBA/2 murine mastocytoma cells. | FA , FC , IHC , in vivo , IP | C797 | PS/2 | |
Alt Names: VLA-4α, ITGA4, Integrin α4 Reactivity: Mouse/Human Immunogen: P815 DBA/2 murine mastocytoma cells. | FA , FC , IHC , in vivo , IP | C798 | PS/2 | |
Alt Names: Major Histocompatibility Class I, MHC class I, human leukocyte antigen (HLA) Reactivity: Baboon ⋅ Chimpanzee ⋅ Cynomolgus Monkey ⋅ Feline ⋅ Bovine ⋅ Human Immunogen: Human tonsil cell membrane | B , FC , IHC FF , in vivo , IP , PhenoCycler® , WB | H263 | W6/32 | |
Alt Names: Major Histocompatibility Class I, MHC class I, human leukocyte antigen (HLA) Reactivity: Baboon ⋅ Chimpanzee ⋅ Cynomolgus Monkey ⋅ Feline ⋅ Bovine ⋅ Human Immunogen: Human tonsil cell membrane | B , FC , IHC FF , in vivo , IP , PhenoCycler® , WB | H463 | W6/32 | |
Alt Names: HLA-DP Monomorphic, HLADP, HLA-DPαβ, DPA and DPB, DPα and DPβ, DPαβ Reactivity: Human Immunogen: Unknown | FC , ICC | H260 | B7/21 | |
Alt Names: HLA-DQ Monomorphic Reactivity: Human Immunogen: Unknown | ELISA , FC , in vivo , IP , WB | H262 | 1a3 | |
Alt Names: HLA-DQ Monomorphic Reactivity: Human Immunogen: Unknown | ELISA , FC , in vivo , IP , WB | H462 | 1a3 | |
Alt Names: Major Histocompatibility Class II, MHC class II, HLA-DR Monomorphic Reactivity: Baboon ⋅ Chimpanzee ⋅ Cynomolgus Monkey ⋅ Marmoset ⋅ Rhesus Monkey ⋅ Squirrel Monkey ⋅ Canine ⋅ Human Immunogen: Unknown | B , CyTOF® , Depletion , FC , IHC FF , in vivo , IP , PhenoCycler® , WB | H261 | L243 | |
Alt Names: Major Histocompatibility Class II, MHC class II, HLA-DR Monomorphic Reactivity: Baboon ⋅ Chimpanzee ⋅ Cynomolgus Monkey ⋅ Marmoset ⋅ Rhesus Monkey ⋅ Squirrel Monkey ⋅ Canine ⋅ Human Immunogen: Unknown | B , CyTOF® , Depletion , FC , IHC FF , in vivo , IP , PhenoCycler® , WB | H461 | L243 |
Can’t find what you’re looking for? Shop all in vivo antibodies.
Generate superior and trusted data with in vivo grade functional antibodies from Leinco Technologies
Leinco Technologies has developed an extensive technology tool box for the manufacturing of monoclonal antibodies for in vitro cellular based experiments or in vivo functional studies in animal models. Reproducibility of pre-clinical studies is paramount in driving research forward towards life-saving therapies and diagnostics. However, the scientific community is facing a “reproducibility crisis,” with 70% of respondents to a recent Nature survey* stating that they have been unable to repeat published results. A significant portion of the reproducibility problem is due to impurities and other variables between similar biological reagents and reference materials. Leinco Technologies aims to solve this problem by offering antibodies that meet the highest purity standards in the industry, with low endotoxin levels (<0.5EU/mg) and minimal aggregates (≥98% monomers as measured by SEC) enabling reproducible science and reliable data. Produced in our cGMP and ISO-certified facility, these in vivo functional antibodies are amenable to a variety of research projects, from in vitro cellular studies to long-term in vivo animal studies. Each antibody is available in custom concentrations and package sizes. In vivo PLATINUMTM antibodies are also pathogen-free and tested by the IDEXX Impact I PCR mouse pathogen profile.
IDEXX IMPACT I (PCR-based) Mouse Pathogen Profile for Purified In vivo PLATINUM™ Grade Antibodies
| Mycoplasma sp. | Mouse adenovirus 1 (MAV1) | Lactate dehydrogenase-elevating virus (LDEV) |
| Mycoplasma pulmonis | Mouse adenovirus 2 (MAV2) | Mouse kidney parvovirus (MKPV) |
| Sendai virus | Murine norovirus (MNV) | Hantaan Virus |
| Mouse hepatitis virus (MHV) | Reovirus 3 (REO3) | Mouse cytomegalovirus (mCMV) |
| Pneumonia virus of mice (PVM) | Mouse rotavirus (EDIM) | K virus |
| Minute virus of mice (MVM) | Ectromelia virus | Mouse thymic virus (MTV) |
| Mouse parvovirus (MPV) | Polyomavirus | Corynebacterium bovis |
| Theiler’s murine encephalomyelitis (TMEV) | Lymphocytic choriomeningitis virus (LCMV) | Corynebacterium sp. |
Lot-to-lot reproducibility enables reproducible science
Antibody consistency is fundamental to reproducible science. Our lot-to-lot quality control (below) demonstrates the superior purity and reproducibility of our antibodies.
Figure 1. Quality control of 9 in vivo antibodies: RMP1-14
In vivo antibodies from Leinco Technologies are subjected to extensive QC to ensure high reproducibility between lots. The example in Figure 1 shows the results for nine lots of RMP1-14 antibody, directed against PD-1. The lots have consistently high purity as indicated by non-reducing and reducing SDS-PAGE (Fig. 1A and 1B). Analysis by size exclusion chromatography gave superimposing chromatograms for all nine lots, with overlapping retention times and minimal baseline noise (Fig. 1C). Endotoxin data for eight lots indicated that all lots were below the specification of ≤ 0.5 EU/mg as determined by the limulus amebocyte lysate (LAL) method (Fig. 1D).
Pure and consistent antibodies avoid potential experimental pitfalls
Minimizing antibody aggregates and reducing the risk for:
- Hypersensitivity or anaphylaxis
- Decreased biological activity
- Renal, heart and other organ failure
- Activation of receptors attempting to block
- Diminished overall efficacy of the antibody
“Ultra-ultra” low endotoxin level and minimizing the effects for:
- Activation of immune cascades leading to inflammation and hypotension
- Metabolic acidosis
Minimizing other impurities and reducing the risk for:
- Anaphylaxis
- False positives in immunoassays
Exceeding customers’ needs:
Our GOLD and PLATINUM in vivo functional antibodies are designed to exceed the stringent demands and rigorous standards required for experiments using cell culture and animal models.
